CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleRevenue is $5.1B, above the global median of $534.05M
- FinancialsAltman Z-Score 2.97: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.58%Above 5Y avg (2.12%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
0.0%Sustainable
Payback Period
28.0 yr
Last Ex-Dividend
Jul 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.59BCNY834.10M · vs all stocks (USD)
Trailing P/E
11.93xRevenue (TTM)
34.20BCNY5.10B · vs all stocks (USD)
Profit Margin
1.31%Beta
0.2170xvs all stocks
52-Week Change
-10.00%vs all stocks
Market Capitalization
5.59BCNY834.10M · vs all stocks (USD)
Enterprise Value
8.82BCNY1.31B · vs all stocks (USD)
Trailing P/E
11.93xPrice to Sales (TTM)
0.1635xPrice to Book (MRQ)
1.01xEnterprise to Revenue
0.2580xEnterprise to EBITDA
9.40xGross Margin
6.33%Profit Margin
1.31%Operating Margin
2.54%Return on Assets (TTM)
3.17%Return on Equity (TTM)
9.72%Revenue (TTM)
34.20BCNY5.10B · vs all stocks (USD)
Revenue per Share (TTM)
63.09CNYUpdated Sep 18, 2026Quarterly Revenue Growth
4.50%Gross Profit (TTM)
2.40BCNY357.44M · vs all stocks (USD)
EBITDA (TTM)
977.08MCNY145.74M · vs all stocks (USD)
Net Income (TTM)
447.92MCNY66.81M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-22.10%Operating Cash Flow (TTM)
759.18MCNY113.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
189.14MCNY28.21M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3540CNYUpdated Sep 18, 2026Trailing Annual Dividend Yield
3.58%vs all stocks
5-Year Average Dividend Yield
2.12%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
676.22MCNYFY2025 · Dec 31, 2025Revenue
33.68BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
31.32BCNYFY2025 · Dec 31, 2025Gross Profit
2.36BCNYFY2025 · Dec 31, 2025Operating Income
999.28MCNY149.05M · vs all stocks (USD)
Pre-tax Income
816.70MCNYFY2025 · Dec 31, 2025Income Tax Expense
212.69MCNYFY2025 · Dec 31, 2025Net Income
604.01MCNYFY2025 · Dec 31, 2025EBIT
984.74MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.20BCNYFY2025 · Dec 31, 2025Research & Development
20.33MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
613.53MCNYFY2025 · Dec 31, 2025Other Operating Expenses
88.31MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
25.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
168.04MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
522.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
522.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
604.01MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-102.77MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-231.79MCNYFY2025 · Dec 31, 2025Free Cash Flow
-468.13MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.51BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
604.01MCNYFY2025 · Dec 31, 2025Other Non-cash Items
179.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-669.80MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-345.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-236.34MCNYFY2025 · Dec 31, 2025Net Acquisitions
-441.85MCNYFY2025 · Dec 31, 2025Purchase of Investments
-96.20MCNYFY2025 · Dec 31, 2025Sale of Investments
106.36MCNYFY2025 · Dec 31, 2025Other Investing Activity
-7.02MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-675.05MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
7.68BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-6.40BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-329.80MCNYFY2025 · Dec 31, 2025Other Financing Charges
-345.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
597.21MCNYFY2025 · Dec 31, 2025Shares Outstanding
564.85MSharesUpdated Sep 18, 2026Float Shares
171.92MSharesUpdated Sep 18, 2026% Held by Insiders
70.59%vs all stocks
% Held by Institutions
0.18%vs all stocks
Total Cash (MRQ)
1.96BCNY291.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.46CNYUpdated Sep 18, 2026Total Debt (MRQ)
4.48BCNY668.30M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7206xCurrent Ratio (MRQ)
1.38xBook Value per Share (MRQ)
9.77CNYUpdated Sep 18, 2026Total Assets
16.78BCNY2.50B · vs all stocks (USD)
Total Current Assets
14.34BCNYFY2025 · Dec 31, 2025Total Liabilities
11.00BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.44BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
490.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
10.51BCNYFY2025 · Dec 31, 2025Cash
1.50BCNYFY2025 · Dec 31, 2025Cash Equivalents
438.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.94BCNYFY2025 · Dec 31, 2025Accounts Receivable
7.31BCNYFY2025 · Dec 31, 2025Inventory
4.29BCNYFY2025 · Dec 31, 2025Accounts Payable
6.04BCNYFY2025 · Dec 31, 2025Short-term Debt
3.02BCNYFY2025 · Dec 31, 2025Other Current Liabilities
621.87MCNYFY2025 · Dec 31, 2025Long-term Debt
384.84MCNYFY2025 · Dec 31, 2025Common Stock (Book)
540.78MCNYFY2025 · Dec 31, 2025Retained Earnings
2.27BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.78BCNY862.26M · vs all stocks (USD)
Treasury Stock
1.66MCNYFY2025 · Dec 31, 202552-Week Low
8.62CNYUpdated Sep 18, 202652-Week High
14.36CNYUpdated Sep 18, 202652-Week Change
-10.00%vs all stocks
Beta
0.2170xvs all stocks
50-Day MA
9.72CNYUpdated Sep 18, 2026200-Day MA
11.08CNYUpdated Sep 18, 2026Avg 10-Day Volume
2.81MSharesUpdated Sep 18, 2026Avg 30-Day Volume
3.98MSharesUpdated Sep 18, 2026Diluted EPS (TTM)
0.8300CNYUpdated Sep 18, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
High ROE Relative To Gross Margin
Its return on equity is high for the gross margin it earns, with revenue up three years and profit in all five.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.97: safe zoneNotable
Altman Z-Score: 2.97
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Revenue is $5.1B, above the global median of $534.05MNotable
Revenue (USD): 5,101,767,564.411Global Median: 534,052,387.958
Levered free cash flow is $28.21M, above the global median of $19.23MNotable
Levered free cash flow (USD): 28,212,847.914Global Median: 19,234,564.734
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Novoprotein Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Celestica Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh ROE Relative To Gross Margin
Goldcup Electric Apparatus Co., Ltd.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh ROE Relative To Gross Margin
Logista Integral, S.A.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthHigh ROE Relative To Gross Margin